Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/3/2008

This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already

adequately treated by antithrombotic therapy

BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine Multaq(R) (dronedarone) on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=0.00000002) as compared to placebo.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoints showed that Multaq(R) decreased the risk of stroke (ischemic or haemorrhagic) compared to placebo by 34% (46 vs 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by standard therapy including antithrombotics.

The significant reduction in stroke risk with Multaq(R) was incremental to background anti-thrombotic therapy like oral anticoagulants and / or anti-platelet agents. Similar to the ATHENA primary endpoint of CV hospitalizations or death, this effect appeared early and was maintained during the study follow-up (12 to 30 months).

"ATHENA is a landmark trial that will lead to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic drug has shown a significant impact on cardiovascular outcomes. As stroke is one of the leading complications of atrial fibrillation, and a major cause of death and long-term disability, these new results demonstrate the unique profile of Multaq(R) beyond its pure rhythm and rate-controlling effects," said Professor Stuart Connolly, Mc Master Uni
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
5. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Arpida Provides Further Comments on the Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Conference, to be held March 8-11, 2015, in ... James Sapirstein , Chief Executive Officer, will provide an ... and will be available to participate in one-on-one meetings ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... nation,s top rehabilitation hospitals for spinal cord injury and ... clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... cord injury (SCI). The Phase 1/2a ...
(Date:3/5/2015)... and VANCOUVER, British Columbia ... BUX FSE: 20B OTCQB: BMKDF) -- The ultimate goal ... assay that is capable of detecting tumors before they ... years, the development of such an assay has been ... academia and industry. Although many breakthrough diagnostics have been ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
... DANBURY, Conn., March 8, 2012  Biodel Inc. (Nasdaq: ... Souza, President and CEO of Biodel, will present a ... Conference on ­­­­­­­­­March 14, 2012 at 3:00 p.m. Pacific ... ROTH 24th Annual OC Growth Stock Conference will be ...
... Germany, March 8, 2012   , ...   QIAGEN,s   digene ... testing for high-risk types of human papillomavirus (HPV), the primary cause ... Day, QIAGEN also joins fifth year of campaign to provide free ...
Cached Medicine Technology:QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics 2QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics 3QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics 4
(Date:3/5/2015)... 05, 2015 Central Nebraska Imaging (CNI) ... including the brand’s new logo and optimized website. ... practice’s modern approach to expert diagnostic imaging, centered on ... be built to be a resource for Nebraska patients ... automated forms, communication and referral functionality, video content and ...
(Date:3/5/2015)... 05, 2015 On March 2, 2015, ... Labiaplasty on the Rise, Plastic Surgeons Say,” that comments ... Society for Aesthetic Plastic Surgery and the ... reported a year-over-year doubling of surgical butt augmentations performed ... in the article, this increase can be attributed to ...
(Date:3/5/2015)... At the 7th Annual Mississippi ... addiction treatment met today in Jackson, Mississippi to listen ... Among the numerous respected speakers will be William ... role that pain medications have had in today’s opiate ... , "It is hard to believe that much of ...
(Date:3/5/2015)... 2015 University of Western States ... 1904, has launched a new center of excellence ... The Northwest Center for Lifestyle and Functional Medicine ... outreach, and conduct research in the areas of ... nutrition. The center will target efforts on the ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... 30 (HealthDay News) -- Winter does have its pluses for ... to get hay fever. But folks tend to spend ... trigger other allergy and asthma problems, experts warn. The ... for keeping yourself sniffle-free if you,re cooped up inside: ...
... News) -- Researchers report that they,ve gained insight into the ... role in how the body stores fat to protect against ... to be linked to both insulin sensitivity and the survival ... between all these different phenomena," Dr. Philipp Scherer, a professor ...
... Gardner HealthDay Reporter , WEDNESDAY, Dec. 29 ... experienced nurse improved the health of patients suffering from ... depression. A study appearing in the Dec. 30 ... reports improvements in the four areas of blood ...
... a new chance at life. But many who receive one ... build up in the lungs and chokes off the ability ... diagnostic tool they developed to predict bronchiolitis obliterans syndrome (BOS) ... life-saving treatments. BOS is the leading cause of death ...
... , WEDNESDAY, Dec. 29 (HealthDay News) -- Federal researchers ... risks facing people with a rare immune system-weakening condition ... personalized treatment. "Advances in treatment of CGD ... disease of early childhood to survive into adulthood; however, ...
... Dec. 29 (HealthDay News) -- Stretching before taking warm-up ... suggests. Doing a passive, static stretching routine before ... speed, distance, accuracy and consistent ball contact," according to ... in Nacogdoches, Texas. He compared two different warm-up ...
Cached Medicine News:Health News:Take Steps to Avoid Winter's Indoor Allergies 2Health News:Research Sheds Light on 'Starvation Hormone' 2Health News:Team-Based Treatment Helps Those With Cluster of Chronic Illnesses 2Health News:Team-Based Treatment Helps Those With Cluster of Chronic Illnesses 3Health News:New test announced for major killer of lung transplant patients 2Health News:U.S. Researchers Find New Way to Gauge Rare Genetic Condition 2Health News:Stretching Before Warm-Up Swings May Harm Golf Game 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: